A licensing deal with Jiangsu Hengrui Pharmaceuticals puts Merck in a competitive race to develop a medicine that targets a ...

Merck (NYSE:MRK) stock in focus as the company partners with Jiangsu Hengrui in a $2B deal for heart disease therapy HRS-5346 ...

Merck has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion, ...

Under terms of the deal, Merck will gain global rights to develop, manufacture, and commercialize HRS-5346 for cardiovascular ...

Merck & Co. is handing over $200 million to China’s Hengrui Pharma for a phase 2-stage lipoprotein(a) (Lp(a)) inhibitor.

Merck & Co. has agreed to license an investigational oral small molecule lipoprotein (a) inhibitor from Jiangsu Hengrui Pharmaceuticals in a deal potentially worth more than $2 billion to the Chinese ...

Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, ...

US pharma giant Merck & Co and China’s Jiangsu Hengrui Pharmaceuticals have entered into an exclusive license agreement for ...

Merck joins a growing list of companies targeting lipoprotein(a), high levels of which are associated with an elevated risk ...

Under the agreement, Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region.

Merck secures global rights to HRS-5346, an investigational Lp(a) inhibitor, in a deal with Hengrui Pharma worth up to $1.97 billion.